- Year selection
- 2020
- 2021
- 2022
- 2023
- 2024
-
2024-03-27
Voluntary Announcement - The first patient was enrolled in the Phase III clinical trial of bisspecific antibody M701 malignant ascites
-
2024-03-26
Voluntary Announcement - First patient enrolled in Phase II clinical trial of bispecial antibody M701 malignant pleural effusion
-
2024-03-15
Date of board meeting
-
2024-03-05
Monthly Return of equity Issuer on Movements in Securities for the month ended 29 February 2024
-
2024-02-28
Notification Letters and Reply Notes to Registered Shareholders - Arrangements for the electronic release of corporate communications
-
2024-02-28
Notification Letters and Reply Notes to non-registered Shareholders - Arrangements for electronic distribution of corporate communications
-
2024-02-05
Monthly return of equity Issuer on movements in securities for the month ended 31 January 2024
-
2024-01-04
Monthly Return of equity Issuer on movements in securities for the month ended 31 December 2023
-
2023-12-05
Monthly Return of equity Issuer on movements in Securities for the month ended 30 November 2023
-
2023-11-16
章程
Email: info@saramaliahatfield.com
Add: Building C2-1, Optics Valley Biologic City, No. 666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan City, Hubei Province
